Analysts Set Humacyte, Inc. (NASDAQ:HUMA) Target Price at $13.71

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been given a consensus recommendation of "Buy" by the eight research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $13.71.

A number of analysts have recently issued reports on the company. HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Humacyte in a research report on Wednesday, March 12th. Benchmark reiterated a "buy" rating on shares of Humacyte in a research report on Thursday, February 27th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research report on Wednesday, March 26th.

Insider Transactions at Humacyte

In other Humacyte news, CFO Dale A. Sander bought 20,000 shares of the firm's stock in a transaction dated Thursday, April 10th. The shares were bought at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the acquisition, the chief financial officer now owns 40,600 shares of the company's stock, valued at approximately $62,118. This trade represents a 97.09 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kathleen Sebelius bought 50,000 shares of the firm's stock in a transaction dated Tuesday, April 8th. The shares were acquired at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the acquisition, the director now directly owns 91,207 shares of the company's stock, valued at approximately $120,393.24. The trade was a 121.34 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 83,993 shares of company stock worth $118,224. Insiders own 11.20% of the company's stock.

Institutional Trading of Humacyte

Large investors have recently made changes to their positions in the business. Columbia Advisory Partners LLC acquired a new position in shares of Humacyte during the first quarter valued at $27,000. Hamilton Lane Advisors LLC acquired a new position in shares of Humacyte during the first quarter valued at $37,000. Vontobel Holding Ltd. acquired a new position in shares of Humacyte during the fourth quarter valued at $50,000. Petros Family Wealth LLC acquired a new position in shares of Humacyte during the fourth quarter valued at $50,000. Finally, Syon Capital LLC acquired a new position in shares of Humacyte during the fourth quarter valued at $54,000. Institutional investors own 44.71% of the company's stock.

Humacyte Price Performance

Shares of HUMA traded up $0.02 on Wednesday, reaching $1.46. 1,326,438 shares of the stock traded hands, compared to its average volume of 3,583,442. The firm has a market cap of $226.47 million, a price-to-earnings ratio of -1.09 and a beta of 1.62. Humacyte has a 12 month low of $1.15 and a 12 month high of $9.97. The stock's 50-day moving average price is $2.32 and its 200-day moving average price is $3.86.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07. The firm had revenue of $7.23 million for the quarter, compared to the consensus estimate of $0.64 million. As a group, equities research analysts forecast that Humacyte will post -1.27 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.